Inhaled Amphotericin B for Chronic Aspergillosis Maintenance
Part of Infections, Lungs & breathing clinical trials.
This study compares two inhaled treatments (amphotericin B vs. saline) to see which one works better as maintenance therapy for people with chronic pulmonary aspergillosis. It aims to find a convenient way to keep the infection under control after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic pulmonary aspergillosis (CPA) and have already been treated with oral itraconazole for 12 months.
- You are not taking high doses of steroids or other immune-suppressing medications.
- You do not have an active lung infection with tuberculosis or other mycobacteria.
- You do not have other forms of aspergillosis, such as invasive infection.
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.
This study compares two antifungal medications (itraconazole and posaconazole) to see which works better for a chronic fungal lung infection called aspergillosis. If you have this condition, taking part may help control your symptoms and improve your quality of life.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This study will use special scans to see how an inhaled antifungal medicine (amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis. The results may help doctors choose better treatments in the future.
This trial compares three treatments for ABPA: a steroid (prednisolone), an antifungal (itraconazole), or both together. It aims to find which works best for controlling symptoms and preventing flare-ups.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
Hear when a new Chronic Pulmonary Aspergillosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.